查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1948933

肺动脉瓣膜人工系统市场（按产品类型、材料类型和最终用户划分），全球预测，2026-2032年

Artificial Pulmonary Valve System Market by Product Type, Material Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工肺动脉瓣膜系统市场价值将达到 13.8 亿美元，到 2026 年将成长至 15.4 亿美元，到 2032 年将达到 34.5 亿美元，复合年增长率为 13.95%。

关键市场统计数据
基准年 2025 13.8亿美元
预计年份：2026年 15.4亿美元
预测年份 2032 34.5亿美元
复合年增长率 (%) 13.95%

提供人工肺动脉瓣系统的临床、技术和商业性背景，以指导经营团队的策略优先排序。

人工肺动脉瓣膜系统的发展现状取决于外科手术创新、微创心臟治疗以及不断变化的患者群体。过去十年，手术流程的改进、生物材料的进步，以及影像技术的提升和病患选择标准的最佳化，都大大拓展了右心室流出道重组的治疗选择。因此，决策者不仅需要评估器材的效能，还必须考虑临床路径、医院准备、医保报销环境以及长期耐久性等因素。

变革性转变重塑肺动脉瓣膜治疗领域的设备开发、临床应用与商业策略

肺动脉瓣领域正经历多重变革，这些变革正在重新定义器材的研发、评估和应用方式。首先，微创介入治疗日益受到青睐，推动了经导管治疗的发展；同时，生物瓣膜材料的改进和抗钙化治疗的进步延长了器械的使用寿命。这些技术进步降低了再次介入率，并影响心臟团队对年轻患者终身管理策略的采纳。

2025年美国关税对肺动脉瓣膜系统供应链、定价结构及商业性进入的累积影响

2025年美国关税调整对製造商和医疗保健系统产生了多方面的营运和商业影响。对某些医疗零件征收的进口关税增加了依赖国际采购的专用原料和成品组件的医疗器材的到岸成本。为应对这一变化，许多製造商加快了近岸外包计划，转移了部分组装业务，并重新谈判了供应商合同，以缓解利润率下降。

关键细分洞察揭示了产品、材料、最终用户、分销管道和年龄层在临床需求、技术契合度和商业性机会方面的交集。

在考虑产品类型时，区分外科植入式肺动脉瓣膜和经导管肺动脉瓣膜至关重要。外科植入式瓣膜分为生物瓣膜和机械瓣膜，而经导管瓣膜则采用球囊扩张型和自扩张式技术，这些技术决定了临床工作流程、培训要求和医院的资金投入。就材料类型而言，与生物瓣膜相比，机械瓣膜和聚合物瓣膜在耐用性和抗凝血效果方面各有优劣。生物瓣膜的进一步差异在于其所用组织为心包组织还是猪组织，这会影响血流动力学和长期钙化。从最终用户的观点，门诊手术中心、医院和专科诊所各自专注于不同的价值因素。门诊中心通常强调手术量和缩短住院通讯协定，医院强调多学科诊疗和复杂病例处理能力，而专科诊所通常作为长期后续观察和器械监测的转诊中心。

区域性洞察，聚焦全球市场在采用曲线、法规环境和报销趋势方面的差异

在美洲，成熟的临床网路和集中式卓越中心支援新型经导管解决方案的快速应用。采购流程深受医院药品清单和全面医疗系统评估的影响。在该地区，对已证实的长期疗效和易于整合到现有导管检查室基础设施的重视，决定了产品上市的顺序以及早期商业化阶段所产生的证据的性质。同时，在欧洲、中东和非洲，监管路径和报销模式各不相同，国家卫生技术评估和区域采购联盟可能会加速或延缓产品的普及。在该地区的许多国家，疗效比较数据和成本效益分析是产品被广泛采用的关键因素。

主要企业洞察：分析领先开发商和新参与企业的竞争定位、平台策略和差异化路径

肺动脉瓣膜领域的竞争优势取决于平台的多功能性、临床证据的深度以及支持全面培训和服务模式的能力。投资于模组化输送平台和多瓣膜技术的领先开发商正受益于交叉销售机会，并减轻其机构客户在特定手术方面的培训负担。新参与企业则透过在生物材料、计算尺寸演算法和简化输送系统方面的专注创新来实现差异化，旨在缩短手术时间并降低对操作者的依赖性。

为产业领导者提供的实用建议：加速临床应用、增强市场进入并优化长期价值交付

行业领导者应优先考虑整合随机数据和真实世界註册研究，以证明药物在不同患者群体中的疗效和长期持久性。使临床试验设计与支付方的证据要求保持一致，将加快报销谈判，并缩短商业性报销决策时间。同时，投资于模组化平台架构和交付系统，最大限度地降低学习曲线，将有助于医院采纳并降低培训成本。在商业性，采用混合分销策略，将与患者量高的中心直接合作，并与患者量低地区的经销商网路结合，将优化覆盖范围和资源配置。

本报告所采用的调查方法支撑了分析的严谨性、资料三角验证和检验过程。

本摘要的分析整合了多方面的证据，以确保分析的严谨性和实际应用价值。透过对临床意见领袖、医疗设备开发商和医疗系统采购负责人的初步调查，我们对医疗器材的推广应用驱动因素、培训需求和支付方参与度进行了定性评估。此外，我们也查阅了二级资讯来源，以了解技术趋势、监管动态和材料科学进展的背景。最后，我们将这些发现与公开的临床试验註册库和同侪审查文献进行交叉检验，以确认其与现有的临床证据相符。

结论：针对相关人员，制定了旨在改善临床疗效和维持商业性成长动能的综合策略要务和后续步骤。

人工肺动脉瓣膜系统的市场格局呈现出一系列引人入胜却又错综复杂的机会，唯有整合创新技术、实证医学证据和市场进入策略，方能把握机会。经导管输送技术和生物材料的进步正在拓展治疗选择，而区域监管环境和报销系统则要求企业制定量身定制的商业策略。能够将模组化产品平台、可靠的临床数据和稳健的供应链结合的企业，将最有可能获得持续的竞争优势。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 肺动脉瓣膜人工系统市场（依产品类型划分）

  • 外科植入式肺动脉瓣
    • 生物瓣膜
    • 机械阀
  • 经导管肺动脉瓣膜
    • 球囊扩张型阀
    • 自膨胀阀

9. 依材料类型分類的肺动脉瓣膜人工系统市场

  • 机械阀
  • 聚合物阀
  • 生物瓣膜
    • 心包组织
    • 猪组织

第十章 肺动脉瓣膜人工系统市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十一章 各地区人工肺动脉瓣膜系统市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 肺动脉瓣膜人工系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国肺动脉瓣膜人工系统市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

14. 美国肺动脉瓣膜人工系统市场

第十五章：中国人工肺动脉瓣膜系统市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Affluent Medical, Inc.
  • Anteris Technologies Pty Ltd
  • Artivion, Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Braile Biomedica Industria e Comercio SA
  • Colibri Heart Valve, LLC
  • Corcym Srl
  • Edwards Lifesciences Corporation
  • Foldax, Inc.
  • Innovalve Bio Medical Ltd.
  • JenaValve Technology, Inc.
  • Labcor Laboratorios Ltda
  • Lepu Medical Technology Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort CardioFlow Medtech Corporation
  • Peijia Medical Devices Co., Ltd.
  • PolyVascular, Inc.
  • TTK Healthcare Limited
  • Venus MedTech（Hangzhou）Inc.
  • Xeltis NV
Product Code: MRR-4F7A6D4FB8F1

The Artificial Pulmonary Valve System Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.54 billion in 2026, with a CAGR of 13.95%, reaching USD 3.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.54 billion
Forecast Year [2032] USD 3.45 billion
CAGR (%) 13.95%

Framing the clinical, technological, and commercial context for artificial pulmonary valve systems to guide executive strategic prioritization

The artificial pulmonary valve system landscape sits at the intersection of surgical innovation, minimally invasive cardiology, and evolving patient demographics. Over the past decade, procedural refinements and biomaterial advances have combined with improved imaging and patient selection to expand therapeutic options for right ventricular outflow tract reconstruction. Consequently, decision-makers must evaluate not only device performance but also clinical pathways, hospital readiness, reimbursement environments, and long-term durability considerations.

This executive summary synthesizes core themes relevant to manufacturers, healthcare providers, and investor stakeholders. It highlights technological inflection points, regulatory and policy pressures, and shifting clinical adoption patterns. The document is designed to orient executives to the most consequential forces shaping development priorities and market access strategies.

Moving forward, readers should interpret the findings through a pragmatic lens: device value is determined by clinical outcomes, procedural efficiency, and the ability to integrate into established care pathways. Accordingly, the subsequent sections emphasize strategic implications, segmentation-specific insights, and actionable recommendations to align R&D, commercial, and regulatory efforts with evolving stakeholder expectations.

Transformative Shifts Reshaping Device Development, Clinical Adoption, and Commercial Strategy in Pulmonary Valve Therapy

The pulmonary valve domain is experiencing multiple simultaneous shifts that are redefining how devices are developed, evaluated, and adopted. First, the growing preference for less invasive interventions has accelerated interest in transcatheter solutions, while refinements in bioprosthetic materials and anti-calcification treatments are extending device longevity. These technical improvements reduce reintervention rates and influence adoption among heart teams that weigh lifetime management strategies for younger patients.

Second, advanced imaging and computational modeling are enabling more precise sizing and procedural planning, which in turn lowers complication rates and expands eligibility for patients with complex right ventricular outflow tract anatomies. As a result, centers of excellence are increasingly capturing higher volumes and acting as early adopters that validate performance claims in real-world settings.

Third, the competitive landscape is being reshaped by modular product architectures and platform strategies that emphasize shared delivery systems and incremental valve upgrades. This approach shortens product cycles and changes commercialization dynamics, with after-sales services and training becoming central to customer retention. Finally, policy and tariff shifts in certain jurisdictions are prompting supply chain diversification and reconsideration of global sourcing strategies, which has downstream implications for cost structures and pricing models.

Cumulative Impact of United States Tariffs Enacted in 2025 on Supply Chains, Pricing Structures, and Commercial Access for Pulmonary Valve Systems

Tariff adjustments introduced in the United States during 2025 have produced a range of operational and commercial effects for manufacturers and health systems. Import duties on certain medical components increased landed costs for devices that rely on specialized raw materials or finished subassemblies sourced internationally. In response, many manufacturers accelerated nearshoring initiatives, relocated select assembly operations, and renegotiated supplier agreements to mitigate margin compression.

These supply chain responses generated short-term logistical complexity, including inventory rebalancing and expanded use of bonded warehouses to smooth fulfillment to hospitals and specialty clinics. Over time, organizations that strategically diversified supplier bases and invested in local manufacturing resilience improved their ability to offer competitive pricing while preserving service levels. Clinically, some hospital procurement groups delayed non-urgent capital purchases as they reassessed total cost of ownership under the new tariff realities, prompting manufacturers to propose flexible pricing constructs or managed entry agreements.

Concurrently, payers and health systems emphasized demonstration of value through outcomes and cost-per-procedure analyses, which increased the importance of post-market evidence generation and outcomes registries. In aggregate, the tariff changes catalyzed a reassessment of global manufacturing footprints and commercial models, with durable advantages accruing to organizations that combined operational agility with compelling clinical evidence.

Key Segmentation Insights That Reveal Where Clinical Need, Technology Fit, and Commercial Opportunity Converge Across Product, Material, End User, Distribution, and Age Cohorts

When examining product type, it is critical to differentiate surgically implanted pulmonary valves from transcatheter pulmonary valves, recognizing that surgically implanted options split into bioprosthetic and mechanical valves while transcatheter offerings are characterized by balloon expandable and self expandable technologies; this distinction drives divergent clinical workflows, training requirements, and hospital capital needs. Regarding material type, mechanical valves and polymer valves present distinct durability and anticoagulation trade-offs compared with tissue valves, with tissue options further differentiated by pericardial tissue and porcine tissue choices that affect hemodynamics and long-term calcification profiles. From the end user perspective, ambulatory surgical centers, hospitals, and specialty clinics each prioritize different value drivers: ambulatory centers emphasize throughput and shorter length-of-stay protocols, hospitals focus on multidisciplinary care coordination and complex-case capability, and specialty clinics often serve as referral hubs for longitudinal follow-up and device surveillance.

Distribution channel dynamics matter because direct sales arrangements allow manufacturers to maintain clinical relationships and provide integrated training, whereas distributor sales offer broader geographic reach and inventory handling that may suit smaller suppliers. Age group segmentation reveals that adult and pediatric populations demand tailored device characteristics and follow-up strategies; the adult cohort subdivides into geriatric, middle aged, and young adult segments, each with unique comorbidity profiles and life-expectancy considerations, while the pediatric cohort subclasses into adolescent, infant, and neonatal groups with distinct anatomical constraints and growth-related management imperatives. Integrating these segmentation lenses clarifies where design priorities, clinical evidence, and commercial investments will most effectively yield adoption and improved patient outcomes.

Regional Insights That Highlight Differential Adoption Curves, Regulatory Environments, and Reimbursement Dynamics Across Global Markets

In the Americas, established clinical networks and concentrated centers of excellence support rapid uptake of novel transcatheter solutions, with procurement processes that are highly influenced by hospital formularies and integrated health system evaluations. This region shows a preference for proof of long-term outcomes and ease of integration into existing cath lab infrastructures, which shapes the sequencing of product launches and the nature of evidence generated during early commercialization phases. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory pathways and reimbursement models where national-level health technology assessments and regional procurement consortia can either accelerate or delay access; in many countries within this region, comparative effectiveness data and cost-effectiveness narratives become decisive for mainstream adoption.

Asia-Pacific markets are characterized by heterogeneous market maturity, ranging from advanced tertiary centers in urban hubs to rapidly developing specialty networks; these markets often emphasize scalable manufacturing partnerships and competitive pricing structures, while clinical opinion leaders in major centers can drive regional adoption through high-visibility case series and training programs. Across all regions, a common theme is the increasing importance of localized clinical evidence and reimbursement strategies tailored to national payment practices, which directly influence the sequencing of market entry and resource allocation for commercial operations.

Key Companies Insights That Distill Competitive Positioning, Platform Strategies, and Differentiation Pathways Among Leading Developers and New Entrants

Competitive positioning in the pulmonary valve domain is being defined by platform versatility, clinical evidence depth, and the ability to support comprehensive training and service models. Leading developers that have invested in modular delivery platforms and multi-valve footprints are benefiting from cross-selling opportunities and lower per-procedure training burdens for institutional customers. New entrants are differentiating through focused innovations in biomaterials, computational sizing algorithms, and simplified delivery systems aimed at reducing procedure time and operator dependency.

Strategic partnerships and licensing arrangements are common, particularly where technology gaps exist around imaging integration or proprietary anti-calcification treatments. Firms that align commercialization strategies with robust post-market surveillance and registry participation improve their credibility with cardiothoracic surgeons and interventional cardiologists. Moreover, companies that establish flexible commercial models-combining direct sales for flagship accounts with distributor partnerships in lower-volume territories-tend to achieve broader geographic penetration while conserving commercial expenditures. Overall, the competitive frontier centers on delivering durable clinical outcomes, streamlined procedural workflows, and demonstrable cost-effectiveness to health systems.

Actionable Recommendations for Industry Leaders to Accelerate Clinical Adoption, Strengthen Market Access, and Optimize Long-Term Value Delivery

Industry leaders should prioritize integrated evidence generation that couples randomized data with real-world registries to demonstrate both efficacy and long-term durability in diverse patient cohorts. Aligning clinical trial design with payer evidence needs facilitates faster reimbursement dialogues and reduces time to commercial reimbursement decisions. In parallel, investing in modular platform architectures and delivery systems that minimize learning curves will ease hospital adoption and reduce training costs. Commercially, a hybrid distribution strategy that combines direct engagement at high-volume centers with distributor networks in lower-volume geographies optimizes reach and resource allocation.

Operationally, companies should pursue supply chain resilience by diversifying suppliers, qualifying secondary manufacturing sites, and establishing contingencies for tariff or trade disruptions. Finally, manufacturers must collaborate proactively with clinical leaders to develop standardized care pathways and device surveillance protocols that enhance patient outcomes and generate the type of longitudinal data that payers and providers value. By executing on these recommendations, organizations can secure sustainable market positions while delivering measurable benefits to patients and health systems.

Research Methodology That Underpins the Analytical Rigor, Data Triangulation, and Validation Processes Employed in the Report

The analysis underpinning this summary combines multiple evidence streams to ensure analytical rigor and practical relevance. Primary research with clinical opinion leaders, device developers, and health system procurement professionals informed qualitative assessments of adoption drivers, training needs, and payer interactions. Secondary sources were reviewed to contextualize technological trends, regulatory developments, and material science advances; these findings were cross-validated against publicly available clinical trial registries and peer-reviewed literature to ensure alignment with established clinical evidence.

In addition, the methodology incorporated scenario analysis to evaluate the operational and commercial implications of supply chain disruptions and policy changes. Validation workshops with independent clinicians and industry advisors were convened to test key assumptions and refine strategic implications. Throughout the process, emphasis was placed on triangulation of insights, transparency in assumptions, and clear articulation of uncertainty to support confident decision-making by executive stakeholders.

Conclusion: Synthesis of Strategic Imperatives and Next Steps for Stakeholders Focused on Improving Clinical Outcomes and Sustaining Commercial Momentum

The artificial pulmonary valve system landscape presents a compelling but complex set of opportunities that reward integrated strategies across innovation, evidence generation, and market access. Technological progress in transcatheter delivery and biomaterials is expanding therapeutic options, while regional regulatory and reimbursement differences require tailored commercial tactics. Organizations that couple modular product platforms with robust clinical data and resilient supply chains will be best positioned to capture durable advantages.

Looking ahead, stakeholders should prioritize investments that reduce procedural complexity, enhance long-term device performance, and generate the localized evidence payers require for reimbursement. Building collaborative relationships with centers of excellence and engaging in post-market surveillance will accelerate trust and broaden adoption. Ultimately, success will hinge on aligning product development with demonstrable improvements in patient outcomes and cost-effectiveness, thereby securing both clinical credibility and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Pulmonary Valve System Market, by Product Type

  • 8.1. Surgically Implanted Pulmonary Valve
    • 8.1.1. Bioprosthetic Valve
    • 8.1.2. Mechanical Valve
  • 8.2. Transcatheter Pulmonary Valve
    • 8.2.1. Balloon Expandable Valve
    • 8.2.2. Self Expandable Valve

9. Artificial Pulmonary Valve System Market, by Material Type

  • 9.1. Mechanical Valve
  • 9.2. Polymer Valve
  • 9.3. Tissue Valve
    • 9.3.1. Pericardial Tissue
    • 9.3.2. Porcine Tissue

10. Artificial Pulmonary Valve System Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Artificial Pulmonary Valve System Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Artificial Pulmonary Valve System Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Artificial Pulmonary Valve System Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Artificial Pulmonary Valve System Market

15. China Artificial Pulmonary Valve System Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Affluent Medical, Inc.
  • 16.7. Anteris Technologies Pty Ltd
  • 16.8. Artivion, Inc.
  • 16.9. BIOTRONIK SE & Co. KG
  • 16.10. Boston Scientific Corporation
  • 16.11. Braile Biomedica Industria e Comercio S.A.
  • 16.12. Colibri Heart Valve, LLC
  • 16.13. Corcym S.r.l.
  • 16.14. Edwards Lifesciences Corporation
  • 16.15. Foldax, Inc.
  • 16.16. Innovalve Bio Medical Ltd.
  • 16.17. JenaValve Technology, Inc.
  • 16.18. Labcor Laboratorios Ltda
  • 16.19. Lepu Medical Technology Co., Ltd.
  • 16.20. LivaNova PLC
  • 16.21. Medtronic plc
  • 16.22. Meril Life Sciences Pvt. Ltd.
  • 16.23. MicroPort CardioFlow Medtech Corporation
  • 16.24. Peijia Medical Devices Co., Ltd.
  • 16.25. PolyVascular, Inc.
  • 16.26. TTK Healthcare Limited
  • 16.27. Venus MedTech (Hangzhou) Inc.
  • 16.28. Xeltis NV

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BIOPROSTHETIC VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BIOPROSTHETIC VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BIOPROSTHETIC VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SELF EXPANDABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SELF EXPANDABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SELF EXPANDABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MECHANICAL VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY POLYMER VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY POLYMER VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY POLYMER VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PERICARDIAL TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PERICARDIAL TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PERICARDIAL TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PORCINE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PORCINE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PORCINE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY SURGICALLY IMPLANTED PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TRANSCATHETER PULMONARY VALVE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY TISSUE VALVE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ARTIFICIAL PULMONARY VALVE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)